Rexahn Pharmaceuticals Granted European Patent for Anti-Cancer Compound

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, Tuesday announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.
Fox Business